No Data
Is Yili Chuanning Biotechnology Co.,Ltd.'s (SZSE:301301) Latest Stock Performance Being Led By Its Strong Fundamentals?
Chuaning Bio (301301.SZ): Plans to postpone the "Shanghai Research Institute Construction Project" to December 31, 2025.
On December 19, 2023, Gelonghui reported that Chuaning Biological (301301.SZ) held the eighth meeting of its second Board of Directors and the seventh meeting of its second Supervisory Board, which approved the proposal concerning the extension of fundraising investment projects. The company agreed to adjust the deadline for the "Shanghai Research Institute Construction Project" to reach the predetermined usable status to December 31, 2025, without changing the total investment amount, implementing subject, or content of the fundraising projects.
Crown Bio (301301.SZ): Research and development investment mainly in the synthetic biology Sector.
On December 16, Gelonghui reported that Chuan Ning Biological (301301.SZ) stated on the investor interaction platform that the company's research and development expenses in the first three quarters of 2024 amounted to 44.0661 million yuan, an increase of 12.82% year-on-year, with a continuous growth in R&D expenses. The main reason for the relatively low proportion of total revenue is that the company's revenue is growing rapidly; the company's R&D investment is mainly in the synthetic biology Sector, which has a relatively high overall R&D input-output ratio.
Chuan Ning Biotech (301301.SZ): Currently, there is no layout for GLP-1 receptor agonists such as semaglutide.
On December 16, Gelonghui reported that Chuan Ning Bio (301301.SZ) stated on the investor interactive platform that the company currently has no plans to expand into the field of GLP-1 receptor agonists such as semaglutide.
We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease
Chuanning Bio (301301.SZ): As of September, the PHA project has completed pilot and mid-scale process validation.
Gelonghui October 23rd | Chuaning Biology (301301.SZ) stated at the investor relations event that as of September, the PHA project has completed small-scale and mid-scale process validation. The fermentation level has reached expectations, even exceeded them; the product cost is expected to reach a lower level within the same industry after full-scale production, and the company is also considering planning in Kazakhstan, where agricultural product costs are lower, to reduce production costs and further open up the international market.
No Data
